​

OncoCyte (OCX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

OCX Stock Forecast

OncoCyte (OCX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $8.08, with a high of $10.00 and a low of $4.25. This represents a 158.97% increase from the last price of $3.12.

$2 $3 $4 $5 $6 $7 $8 $9 $10 High: $10 Avg: $8.08 Low: $4.25 Last Closed Price: $3.12

OCX Stock Rating

OncoCyte stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (55.56%), 4 Hold (44.44%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 4 5 Strong Sell Sell Hold Buy Strong Buy

OCX Price Target Upside V Benchmarks

TypeNameUpside
StockOncoCyte158.97%
SectorHealthcare Stocks 30.37%
IndustryBiotech Stocks 73.37%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.12$3.12$3.12
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25112--4
Mar, 251-2--3
Feb, 251-2--3
Jan, 251-2--3
Dec, 241-2--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 24, 2024Mike MatsonNeedham$4.25$2.3878.57%36.22%
Dec 01, 2022Lake Street$10.00$9.445.93%220.51%
Nov 18, 2022Piper Sandler$10.00$8.5217.37%220.51%
Aug 17, 2022David WestenbergPiper Sandler$30.00$17.4871.62%861.54%
Aug 11, 2022Lake Street$60.00$19.27211.36%1823.08%
Aug 11, 2022Needham$42.00$19.02120.82%1246.15%
May 15, 2022David WestenbergPiper Sandler$28.00$22.6023.89%797.44%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2024NeedhamBuyBuyhold
May 16, 2024StephensBuyBuyhold
Apr 24, 2024NeedhamBuyBuyhold
Nov 18, 2022Piper SandlerOverweightNeutraldowngrade
Nov 14, 2022Piper SandlerOverweightOverweighthold
Nov 11, 2022NeedhamBuyBuyhold
Aug 17, 2022Piper SandlerOverweightOverweighthold
Aug 11, 2022Lake StreetBuyBuyhold
Aug 11, 2022NeedhamBuyBuyhold
May 15, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-9.14$-14.42$-13.26$-3.75$-4.64--
Avg Forecast$-9.65$-8.20$-7.17$-1.30$-2.74$-1.54$-1.36
High Forecast$-7.49$-6.36$-4.52$-0.59$-1.24$-0.69$-1.16
Low Forecast$-11.44$-9.72$-9.41$-1.90$-4.01$-2.25$-1.55
Surprise %-5.28%75.85%84.94%188.46%69.34%--

Revenue Forecast

$0 $2M $4M $5M $7M $9M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$1.22M$7.73M$958.00K$1.50M$1.88M--
Avg Forecast$1.50M$7.82M$5.94M$1.42M$500.00K$1.03M$5.70M
High Forecast$1.71M$8.93M$7.37M$1.93M$678.25K$1.40M$7.73M
Low Forecast$1.24M$6.47M$4.25M$820.01K$288.84K$596.16K$3.29M
Surprise %-18.96%-1.16%-83.87%5.88%276.20%--

Net Income Forecast

$-90M $-73M $-56M $-39M $-22M $-5M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-29.93M$-64.10M$-73.44M$-27.78M$-60.66M--
Avg Forecast$-73.83M$-62.74M$-34.66M$-25.80M$-20.07M$-11.25M$-10.37M
High Forecast$-57.30M$-48.69M$-27.73M$-20.64M$-9.45M$-5.30M$-8.88M
Low Forecast$-87.49M$-74.35M$-41.60M$-30.96M$-30.68M$-17.21M$-11.86M
Surprise %-59.46%2.17%111.86%7.69%202.31%--

OCX Forecast FAQ

Is OncoCyte stock a buy?

OncoCyte stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that OncoCyte is a favorable investment for most analysts.

What is OncoCyte's price target?

OncoCyte's price target, set by 9 Wall Street analysts, averages $8.08 over the next 12 months. The price target range spans from $4.25 at the low end to $10 at the high end, suggesting a potential 158.97% change from the previous closing price of $3.12.

How does OncoCyte stock forecast compare to its benchmarks?

OncoCyte's stock forecast shows a 158.97% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the biotech stocks industry (73.37%).

What is the breakdown of analyst ratings for OncoCyte over the past three months?

  • April 2025: 25.00% Strong Buy, 25.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is OncoCyte’s EPS forecast?

OncoCyte's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.54, marking a -66.81% decrease from the reported $-4.64 in 2024. Estimates for the following years are.

What is OncoCyte’s revenue forecast?

OncoCyte's average annual revenue forecast for its fiscal year ending in December 2025 is $1.03M, reflecting a -45.14% decrease from the reported $1.88M in 2024. The forecast for.

What is OncoCyte’s net income forecast?

OncoCyte's net income forecast for the fiscal year ending in December 2025 stands at $-11.254M, representing a -81.45% decrease from the reported $-60.663M in 2024. Projections indicate .